Prenatal testing

Point-of-Care Molecular Diagnostics Market Expected to Reach USD 10.12 Billion by 2030, Driven by Technological Advancements and Growing Geriatric Population - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 9, 2024
COVID-19, Telemedicine, Virtual Medicine, Other Health, Pharmaceutical, Practice Management, Oncology, Medical Devices, Infectious Diseases, Hospitals, Science, Biotechnology, AIDS, Other Science, Health, Medical Supplies, Ageing, NGS, Infection, Research, Molecular diagnostics, Prenatal testing, CRISPR, Prenatal development, Cancer, Point, USD, HIV, POC, PCR, Compound annual growth rate, Growth

Recent findings suggest an impending upsurge in the global Point-of-Care (POC) Molecular Diagnostics market, with forecasts estimating a valuation of USD 10.12 billion by the year 2030.

Key Points: 
  • Recent findings suggest an impending upsurge in the global Point-of-Care (POC) Molecular Diagnostics market, with forecasts estimating a valuation of USD 10.12 billion by the year 2030.
  • This relates to a Compound Annual Growth Rate (CAGR) of 2.5% over the period from 2024 to 2030.
  • The market analysis indicates a substantial need for POC molecular diagnostics, particularly for infections like COVID-19 and HIV, and to bolster ongoing monitoring in home healthcare settings.
  • The research addresses crucial data that underpin strategic decisions and forecasted growth, setting the stage for ongoing and future developments in the POC molecular diagnostics landscape.

BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn

Retrieved on: 
Tuesday, December 12, 2023
QCT, Food and Drug Administration, AZALEA, Johnson & Johnson, DNA, Food, Risk, Clinical trial, RBC, European, Anemia, LDT, FDA, Blood, IDE, Janssen Pharmaceuticals, Prenatal testing, Doctor of Philosophy, NGS, HDFN, Investigational device exemption, Kell, Fetus, Viscosity, RHD (gene), Vaccine

MENLO PARK, Calif., Dec. 12, 2023 /PRNewswire/ -- BillionToOne (BTO), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, is pleased to announce a global collaboration with Janssen Research & Development, LLC, a Johnson & Johnson company (Johnson & Johnson), in the AZALEA Phase 3 clinical trial of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN). BTO will provide its UNITY Fetal Antigen Non-invasive Prenatal Test Clinical Trial Assay (UNITY Fetal Antigen CTA), which will serve as a screening assay to help determine the eligibility of pregnant individuals to be included in the trial, which will be conducted in the United States, the European Union, and other select countries in the rest of the world. HDFN is a serious and rare condition which occurs when the blood types of a pregnant individual and the fetus are incompatible, potentially causing life-threatening anemia in the fetus or infant.1

Key Points: 
  • "The ability to detect fetal antigens as early as 10 weeks is only made possible due to our expertise in fetal DNA quantification.
  • The UNITY Fetal Antigen CTA is just one of the many applications of our QCT technology's capabilities."
  • Earlier this year, BillionToOne also published clinical validation data of the UNITY Fetal Antigen Laboratory Developed Test (LDT)2.
  • Additionally, the UNITY Fetal Antigen LDT results were 100% concordant with corresponding neonatal antigen genotype/serology for 23 RhD-negative pregnant individuals and 93 antigen evaluations in 30 alloimmunized pregnancies.2

XiFin Launches New Lab Volume Index (LVI): Delivers Deeper Insights in Post-Pandemic Diagnostic Testing

Retrieved on: 
Wednesday, August 30, 2023
Software, Practice Management, Telemedicine, Virtual Medicine, General Health, Health, Artificial Intelligence, Health Technology, Technology, UBS, Workflow, RCM, Pathology, Prenatal testing, Intelligence, Multimedia, COVID, Managed care, Holiday, Investment, Laboratory, Webcast, Engineering, Pain management, Toxicology, Genetic testing, Internationalized domain name, NYSE, LVI, Microbiology, Cryptocurrency, Pharmaceutical industry

The LVI insights and trends are derived from claims transaction data from within the award-winning XiFin RPM platform .

Key Points: 
  • The LVI insights and trends are derived from claims transaction data from within the award-winning XiFin RPM platform .
  • For example, if the Lab Volume Index is selected for molecular and genetic, it shows the testing volume of all molecular and genetic testing, irrespective of whether it was performed at a hospital lab, a clinical lab, one that primarily does pain management and toxicology, or a lab specializing in molecular testing.
  • The enhanced XiFin Lab Volume Index also features a new user-selectable baseline for 2019 -2022, making it possible to compare the time going forward including annually.
  • Because the COVID volume is historically significant, the original XiFin Lab Volume Index was measured weekly to trend the surges and lulls that happened quickly during the pandemic.

Diagnostic Labs Market Forecast to 2028: Focus on Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, Non-invasive Prenatal Testing, COVID-19 Testing - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022
Health, General Health, COVID-19 testing, Patient, COVID-19, Conditional sentence, Degenerative disease, POCT, Technology, Cancer, Research, Diagnosis, WHO, Insurance, Death, Inter, Artificial intelligence, Disease, Solution, Robotics, Incidence, Educational Testing Service, Pathology, Risk, Prenatal testing, Physician, IOT, General officer, Data management, Others, Laboratory, Infection, Software as a service, Disability, Severe acute respiratory syndrome coronavirus 2, Prevalence, CAGR, World, Efficiency, World Health Organization, Diabetes, Ecosystem, Growth, The, Chronic condition, Health, Pharmaceutical industry, Medical device, Vaccine, Medical imaging

The "Diagnostic Labs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Lab Type, Testing Services [Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, Non-invasive Prenatal Testing, COVID-19 Testing, and Others], Revenue" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diagnostic Labs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Lab Type, Testing Services [Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, Non-invasive Prenatal Testing, COVID-19 Testing, and Others], Revenue" report has been added to ResearchAndMarkets.com's offering.
  • The increasing prevalence of chronic diseases, increasing use of point-of-care diagnostics, and rising healthcare expenditures bolster the growth of the diagnostic labs market.
  • Additionally, the growing developments in diagnostics laboratories are likely to emerge as a significant future trend in the diagnostic labs market from 2022 to 2028.
  • A diagnostic laboratory means an institution (or facility within an institution) equipped with apparatus and reagents for performing diagnostic tests for human infections.

GLOBAL DOWN SYNDROME FOUNDATION PUBLISHES FAMILY-FRIENDLY VERSION OF GLOBAL MEDICAL CARE GUIDELINES FOR ADULTS WITH DOWN SYNDROME

Retrieved on: 
Thursday, June 23, 2022
GLOBE, Patient, University, Adult, Diabetes, Color, Instagram, Behavior, National, American Medical Association, Down syndrome, Anschutz Medical Campus, CO, Cardiovascular disease, Osteoporosis, Thyroid disease, Guideline, Degenerative disease, Research, CEO, Social media, Sleep apnea, Dementia, Lymphatic system, Axis (anatomy), Prenatal testing, Congress, Obesity, Journal, Facebook, Dietary supplement, Pharmaceutical industry

Denver, CO, June 23, 2022 (GLOBE NEWSWIRE) -- Today, Global Down Syndrome Foundation (GLOBAL) announced the publication of a family-friendly version of the GLOBAL Medical Care Guidelines for Adults with Down Syndrome (GLOBAL Adult Guideline).

Key Points: 
  • Denver, CO, June 23, 2022 (GLOBE NEWSWIRE) -- Today, Global Down Syndrome Foundation (GLOBAL) announced the publication of a family-friendly version of the GLOBAL Medical Care Guidelines for Adults with Down Syndrome (GLOBAL Adult Guideline).
  • The Family-Friendly GLOBAL Adult Guideline has helpful pull-out quotes, large photos and font, and is color coded by medical topic.
  • To learn more about the GLOBAL Guideline, visit www.globaldownsyndrome.org/medical-care-guidelines-for-adults/
    To learn more about Global Down Syndrome Foundation, visit www.globaldownsyndrome.org
    The Global Down Syndrome Foundation (GLOBAL) is the largest non-profit in the U.S. working to save lives and dramatically improve health outcomes for people with Down syndrome.
  • GLOBALs widely circulated medical publications include Global Medical Care Guidelines for Adults with Down Syndrome , Prenatal Testing and Information about Down Syndrome , and the award-winning magazine Down Syndrome World TM .

Largest Down Syndrome Fundraiser In The World To Help Improve & Save Lives

Retrieved on: 
Tuesday, June 21, 2022
People, Linda, CU, Down syndrome, Quinone, Micah, Athlete, National, Government, CEO, Author, Prenatal testing, Joseph, Autism, Children's Hospital Colorado, Research, Anschutz Medical Campus, The Last Ship, Congress, GLOBE, University, Health, Record, Anna, Social media, 15th Screen Actors Guild Awards, Health Beauty Life, Patient, Facebook, Instagram, CO, COVID, Life, NIH, Film, Pharmaceutical industry, Euphoria, Parent, People (magazine), Burlesque

Im excited to be chairing this years fashion show and so proud to see Micah honored as a GLOBAL Ambassador, says Amanda Booth.

Key Points: 
  • Im excited to be chairing this years fashion show and so proud to see Micah honored as a GLOBAL Ambassador, says Amanda Booth.
  • The Global Down Syndrome Foundation (GLOBAL) is the largest non-profit in the U.S. working to save lives and dramatically improve health outcomes for people with Down syndrome.
  • GLOBALs widely circulated medical publications include Global Medical Care Guidelines for Adults with Down Syndrome , Prenatal Testing and Information about Down Syndrome , and the award-winning magazine Down Syndrome WorldTM .
  • GLOBAL also organizes the Be Beautiful Be Yourself Fashion Show , the largest Down syndrome fundraiser in the world.

5-Time Olympic Medalist Elana Meyers Taylor Joins Global Down Syndrome Foundation As New International Spokesperson

Retrieved on: 
Thursday, June 16, 2022
Winter Olympic Games, Down syndrome, Sport, World championship, CEO, Mother, Prenatal testing, Woman, Man, Research, Anschutz Medical Campus, Congress, GLOBE, National, University, Family, Partnership, History, Social media, Patient, Facebook, Silver, Instagram, CO, Life, NIH, Pharmaceutical industry, Medicine

Elanas dedication, acumen, kindness, passion, and advocacy experience is already helping GLOBAL and the people with Down syndrome we serve.

Key Points: 
  • Elanas dedication, acumen, kindness, passion, and advocacy experience is already helping GLOBAL and the people with Down syndrome we serve.
  • I am truly honored to be an International Spokesperson for the Global Down Syndrome Foundation, says Taylor.
  • The Global Down Syndrome Foundation (GLOBAL) is the largest non-profit in the U.S. working to save lives and dramatically improve health outcomes for people with Down syndrome.
  • GLOBAL also organizes the Be Beautiful Be Yourself Fashion Show , the largest Down syndrome fundraiser in the world.

Global Down Syndrome Foundation Raises $400,000 at Their AcceptAbility Gala in Washington, DC

Retrieved on: 
Thursday, May 26, 2022
Fox News, Death, Social media, American Authors, Patient, Down syndrome, Washington Marriott Marquis, Anschutz Medical Campus, Autism, NIH, Research, The Washington Times, Facebook, Student, Instagram, Congress, University, ABC, Love, National, Friends, Caroline Bird (American author), Prenatal testing, CEO, GLOBE, Pharmaceutical industry

Washington, DC, May 26, 2022 (GLOBE NEWSWIRE) -- Tuesday evening, the Global Down Syndrome Foundation (GLOBAL) held its annual AcceptAbility Gala at the Marriott Marquis Washington, DC.

Key Points: 
  • Washington, DC, May 26, 2022 (GLOBE NEWSWIRE) -- Tuesday evening, the Global Down Syndrome Foundation (GLOBAL) held its annual AcceptAbility Gala at the Marriott Marquis Washington, DC.
  • The event attracted nearly 300 attendees and raised $400,000 for life-changing research and medical care for people with Down syndrome.
  • Read Senator Steve Daines op-ed, Individuals With Down Syndrome Deserve Better , written in solidarity with GLOBALs AcceptAbility Gala in The Washington Times.
  • The Global Down Syndrome Foundation (GLOBAL) is the largest non-profit in the U.S. working to save lives and dramatically improve health outcomes for people with Down syndrome.

AcceptAbility Gala to Raise Critical Funds and Awareness for Life-Changing Research and Medical Care for People With Down Syndrome

Retrieved on: 
Thursday, May 12, 2022
Fox News, Social media, Patient, Down syndrome, Washington Marriott Marquis, Anschutz Medical Campus, Research, Facebook, Awareness, Instagram, Congress, Olympic, University, ABC, National, Prenatal testing, GLOBE, Pharmaceutical industry, American Authors

The event will raise critical funds and awareness for life-changing research and medical care for people with Down syndrome.

Key Points: 
  • The event will raise critical funds and awareness for life-changing research and medical care for people with Down syndrome.
  • GLOBAL is the leading Down syndrome research and medical care non-profit in the United States.
  • The AcceptAbility Gala honors GLOBALs champions and celebrates the contributions of people with Down syndrome.
  • GLOBALs widely circulated medical publications include Global Medical Care Guidelines for Adults with Down Syndrome , Prenatal Testing and Information about Down Syndrome , and the award-winning magazine Down Syndrome WorldTM .

Global Down Syndrome Foundation, the National Down Syndrome Congress, and the National Down Syndrome Society Highlight the FDA’s Public Warning About Risks Associated with Non-Invasive Prenatal Screening Tests

Retrieved on: 
Wednesday, April 27, 2022
PTP, DNA, American Academy, NIPS, CEO, Blood, Pregnancy, Down syndrome, Parent, National Down Syndrome Congress, Patient, NIPT, Adolescence, FDA, GLOBE, Lists of diseases, National Down Syndrome Society, Prenatal testing, Organization, Device, Food, Fetus, Â, NDSS, Physician, Congress, Pediatrics (journal), Risk, FDA Center for Devices and Radiological Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dietary supplement, Pharmaceutical industry, Pediatrics

Together, GLOBAL, NDSC, and NDSS publish the Prenatal Testing and Information about Down Syndrome (PTP) , the nations most widely distributed pamphlet about NIPS and Down syndrome.

Key Points: 
  • Together, GLOBAL, NDSC, and NDSS publish the Prenatal Testing and Information about Down Syndrome (PTP) , the nations most widely distributed pamphlet about NIPS and Down syndrome.
  • It is very important that the public understands the limitations of these screening tests, added Jordan Kough, Executive Director of NDSC.
  • The National Down Syndrome Congress is a not-for-profit organization dedicated to an improved world for individuals with Down syndrome.
  • The National Down Syndrome Society is the leading human rights organization for all individuals with Down syndrome.